APOGEE THERAPEUTICS, INC.

Analyst Reco. Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
41.69 ^USD	-1.01%		-8.65%	+49.21%

May. 28	Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors	CI
May. 15	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target	May. 10	MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating	Mar. 06	MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating	Mar. 05	MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating	Jan. 03	MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43	Dec. 20	MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating	23-08-08	MT
Stifel Initiates Apogee Therapeutics With Buy Rating, $34 Price Target	23-08-08	MT
Jefferies Initiates Apogee Therapeutics With Buy Rating, $29 Price Target	23-08-08	MT
Guggenheim Starts Apogee Therapeutics With Buy Rating, $29 Price Target	23-08-08	MT
Wedbush Initiates Apogee Therapeutics at Outperform With $40 Price Target	23-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer